"Daratumumab Ready To Move To Front Line In Multiple Myeloma - Roxanne Nelson, RN, BSN"
The novel monoclonal antibody product daratumumab (Darzalex, Janssen) is already used for multiple myeloma in patients who have progressed on other therapies, but now it has been propelled to the front line. New results show that it also improves outcomes in patients with newly diagnosed multiple myeloma who are ineligible for transplant, when used in combination with triple therapy. "What is important about this study is that while daratumumab has been studied and approved for use in patients with relapsed/refractory multiple myeloma, this is the first study to look at it as a front-line agent in newly diagnosed patients," said Ajai Chari, MD, associate professor of medicine, hematology and medical oncology, director of clinical research in the Multiple Myeloma Program, associate director of clinical research at the Mount Sinai Cancer Clinical Trials Office at the Icahn School of Medicine at Mount Sinai. "We may be now looking at an alternative therapy for front-line treatment, in those who are ineligible for transplantation," added. Dr. Chari.
- Ajai Chari, MD, Associate Professor, Medicine, Hematology, Medical Oncology, Director, Clinical Research in the Multiple Myeloma Program, Associate Director, Clinical Research, Mount Sinai Cancer Clinical Trials Office, Icahn School of Medicine at Mount Sinai
Study Reveals New Insights Into Immune System Role in Lung Cancer Risk
Feb 22, 2024 View All Press ReleasesMount Sinai’s Staten Island Cancer Center Moves to New Site
Nov 09, 2023 View All Press Releases
Scientists Create Most Powerful, Accurate Tool Yet to Research Deadliest Blood Cancer
Apr 18, 2023 View All Press Releases
Researchers Find Treatment Options for Patients Whose Blood Cancer Relapses After CAR-T
Nov 04, 2022 View All Press Releases
Study Identifies New Gene That Drives Colon Cancer
Oct 14, 2022 View All Press Releases